Y
Ying Yuan
Publications - 7
Citations - 54
Ying Yuan is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 7 publications receiving 54 citations.
Papers
More filters
Journal ArticleDOI
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Lionel Ades,Larisa Girshova,Vadim A Doronin,María Díez-Campelo,David Valcárcel,Suman Kambhampati,Nora Viniou,Dariusz Woszczyk,R. de Paz Arias,Argiris Symeonidis,Achilles Anagnostopoulos,Eduardo Munhoz,Uwe Platzbecker,Valeria Santini,Robert Fram,Ying Yuan,Sharon Friedlander,Douglas V. Faller,Mikkael A. Sekeres +18 more
TL;DR: The results underscore the importance of large, randomized controlled trials in these heterogeneous myeloid diseases and the value of remaining on therapy >3 cycles.
Journal ArticleDOI
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study
James A. Welker,Carlos D Malvestutto,Olivia K. Giddings,Ella Li,Jian Chen,Kun He,Davis Gates,Amarjot Kaur,Jamie Chen,Martin Devenport,Raymond Touomou,Shyam Kottilil,Yang Liu,Pan Zheng,Yang Liu,Hung-Yen Chou,Jai Thakor,I. Khan,Nicole Bright Do,Josephine Faragalla,Andrea Hook,Sarah Kern,Janira V. Ramos,J. Ward,J. C. Higson,Meena Dam,Dawn Serkin,Pooja Karloopia,Wendy Moore,Mark Scofield,David J. Childers,Jeffrey S. Cantrell,Millie Corgan,Xiang Zhou,Jing Liu,Denise Redvers-Higgins,Huatao Han,Jiyun Hou,Yu-bin Pan,Karyn Tucker,Xiaoyan Zhang,Joel V Chua,Jennifer Husson,S. Narayanan,Jaqueline Bran,Ka Wing J. Lam,Alicia Jeffrey,Jennie Pexa,Mario Becerra,James Welker,Kathleen Gray,Nicole Richmond,C. O. Nzelibe,Susan L. Koletar,Mahdee Sobhanie,Jason Clark,Zihai Li,Kelsi Reynolds,K. Chakravarthy,Kevin Blair Weller,M. Yusuf,Jennifer Severing,Kelley Barley,Juan D. Pulido,Jennifer C. Fulton,William Gil,M.D. Jeanine,Richmond R.N.,Sandy Jones,Kristina Clemmer,Dana Byrne,Lisa Pedroza,E. Davidson,Amanda Logan,Katie Grant,Eric D. Whitman,Jason S. Kessler,Robert Roland,Rosemary Stefiniw,M. Maurer,Salome Geene,C. F. Buck,Debra Connolly,Patrice Light,Sunanda Baviskar,Y.W. Low,Krzysztof A. Michalski,Pamela Giordano,Jennifer Chao,Michelle Williams,A K Makkapati,Andrew T. Catanzaro,Jonathan Cohen,Mehad Musbah,Pramila Jaladanki,Ying Yuan,Shilpa Rele,Desirae Stewart,Starlet Lewis,I. Jai Sankar,Nabulungi Kasumba,Kaylia Biney,E. Ali Hekmat,Jordan E. Lake,Bindu Akkanti,Melissa J. Reimer-McAtee,Marisel Negret Hernandez +106 more
TL;DR: CD24Fc is generally well tolerated and accelerates clinical improvement of hospitalised patients with COVID-19 who are receiving oxygen support and suggests that targeting inflammation in response to tissue injuries might provide a therapeutic option for patients hospitalised with CO VID-19.
Journal ArticleDOI
Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep).
Jiarui Li,Yuejuan Cheng,Chunmei Bai,Jianming Xu,Lin Shen,Jie Li,Zhi-Yang Zhou,Zhiping Li,Yihebali Chi,Jianjun Yu,E. Li,N. Xu,Tian Liu,Wenhui Lou,Y. Bai,Xianglin Yuan,Xiuwen Wang,Ying Yuan,Jia Chen,Shan Guan,Songhua Fan,W. Su +21 more
TL;DR: In this article , the authors investigated the health-related quality of life (HRQoL) of patients who had neuroendocrine tumors (NETs) from SANET trials and found that patients treated with surufatinib had significantly longer TUDD for dyspnea (hazard ratio [HR] 0.58; 95% confidence interval [CI], 0.39-0.86; P = 0.10; P < 0.0001).
Journal ArticleDOI
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
Leo I. Gordon,Reem Karmali,Jason B. Kaplan,Rakesh Popat,Howard A. Burris,Silvia Ferrari,Sumit Madan,Manesh R. Patel,Giuseppe Gritti,Dima El-Sharkawi,F. I. Chau,John Radford,Jaime Pérez de Oteyza,Pier Luigi Zinzani,Swaminathan P. Iyer,William Townsend,Harry Miao,Igor Proscurshim,Shining Wang,Shilpi Katyayan,Ying Yuan,Jiaxi Zhu,Kate Stumpo,Yaping Shou,Cecilia Carpio,Francesc Bosch +25 more
TL;DR: In this paper , an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-based inhibitor mivavotinib was presented.
Journal ArticleDOI
DROID: Dose-ranging approach to optimizing dose in oncology drug development.
Beibei Guo,Ying Yuan +1 more
TL;DR: The simulation study shows that DROID substantially outperforms the conventional approach, providing a new paradigm to optimize the dose of targeted oncology drugs.